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Heart J 2014;35:657–64.REPLY: Diagnostic Value of Quantitative CMR
in Patients Suspected of Having Myocarditis:
A Question of TimingWe thank Dr. Luetkens and colleagues for their in-
terest in our work (1). We agree that all novel diag-
nostic techniques require careful evaluation before
clinical implementation, but some aspects of Luetk-
ens et al. require clariﬁcation.
In particular, we disagree that our inhomogeneous
patient population represents a major limitation. Dr.
Luetkens and colleagues outlined in their letter an
idealized course of myocarditis, which is not reﬂect-
ing clinical reality. It is essential to appreciate that
myocarditis is a complex disease with variable pre-
sentations and courses (2,3). Importantly, the sub-
acute phase of myocarditis can last with persisting
inﬂammation for several months (3). Thus, there is no
uniform “natural course” of myocarditis as suggested
by Luetkens et al. Real-life patients present at various
stages and with various intervals between onset of
symptoms and presentation for diagnostic evalua-
tion. We therefore think that the heterogeneity of ourlarge, consecutive, and unselected study population
is a strength rather than a limitation, because this
population is fully representative for patients with
clinically deﬁned myocarditis in our tertiary center
(1).
Luetkens et al. also questioned the performance
of T2 mapping in our study. However, global
myocardial T2 values in our patients and control
subjects agree well with previously reported T2 values
in normal and inﬂamed myocardium (4). We therefore
assume the inclusion of more chronic myocarditis
stages as the main explanation for the modest per-
formance of T2 mapping in our study. Indeed, there
may be a role for T2 mapping to assess disease activity
in myocarditis. However, this aspect was not the focus
of our study, but could be an interesting topic for a
future, biopsy-controlled study.
Finally, we did not address the potential confounding
effect of diabetes mellitus on the performance of
extracellular volume. However, the same problem also
applies to other quantitative cardiac magnetic resonance
parameters, such as native T1 values, which are affected
by myocardial ﬁbrosis. The relevance of this aspect
should be addressed in future studies including a sig-
niﬁcant number of patients with myocarditis and po-
tential confounders such as diabetes mellitus, to provide
meaningful conclusions on this issue.
In summary, we do not see that the issues raised by
Dr. Luetkens and colleagues substantially challenge
the major ﬁndings and implications of our study.Ulf K. Radunski, MD
Gunnar K. Lund, MD
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